PRME
Prime Medicine, Inc. Health Care Biological Products, (No Diagnostic Substances) Russell 3000
$4.72Close
$852.0MMarket cap
$2.70 – $5.3652-week range
Nov 6, 2026Next report
Highlights
Strengths
- Leading the market RS 91 · stronger than 91% of stocks over 12 months
Cautions
- Trend not confirmed 7 of 8 conditions · 150-day under the 200-day
- Results soon Nov 6, 2026, in 5 days
- Financial distress Altman Z″ in the distress zone
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
12%
1wk
up 28.6%
price change
1mo
up 54.5%
price change
12-month return
up 9%
market up 11% ·
its own down 7%
F-score
—
— Not assessed
Altman Z
-2.81
Elevated risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
7.0×
price / book
Earnings yield
down 26.4%
EBIT / enterprise value
Cheaper than
10%
of the market · expensive
Revenue growth
up 55%
year on year
EPS growth
—
latest quarter
Sales growth
—
latest quarter
ROE
down 147%
return on equity
Free cash margin
down 3607%
-$167.1M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Trade setup
ATR%
9.6%
$0.45 a day · 2×ATR $3.81
RS
91 / 99
vs the universe
Trend
7 / 8
150-day under the 200-day
Relative volume
1.5×
vs 50-day average
Up/down volume
0.86
50 sessions
Implied move
—
no option chain · report Nov 6, 2026
Trend template · 7 of 8
- 150-day average above the 200-day: fails
Screen verdict
Did not qualify for any screen.
Warning signs
- Bankruptcy model reads distressed The Altman score sits inside the range historically associated with financial distress. It is used here only to exclude, never to rank, and it is a statistical band rather than a prediction about this company.
- Shareholders diluted The share count rose 37.6% over the year, from 131m to 181m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported
Aug 6, 2026
Results reaction
Aug 6, 20260% vs market2 sessions after results
Financials
- Net -4342%
- Free cash -3607%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $5.2M | $0 | $0 | $0 | $3.0M | $4.6M |
| Operating income | -$932,000 | -$84.5M | -$116.5M | -$204.8M | -$202.5M | -$208.3M |
| Net income | -$3.4M | -$165.4M | -$121.8M | -$198.1M | -$195.9M | -$201.1M |
| Net margin | -65% | — | — | — | -6567% | -4342% |
| Earnings per share | -$1.29 | -$12.75 | -$3.59 | -$2.18 | -$1.65 | -$1.35 |
| Free cash flow | -$6.2M | -$38.2M | -$147.9M | -$174.1M | -$130.2M | -$167.1M |
| Free cash margin | -119% | — | — | — | -4363% | -3607% |
| Cash | $37.0M | $185.4M | $187.6M | $41.6M | $182.5M | $63.0M |
| Shareholders' equity | $2.3M | -$156.2M | $316.3M | $133.1M | $153.1M | $120.9M |
| Shares outstanding | — | 32.41m | 97.21m | 97.38m | 131.16m | 180.51m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 6, 2026 | Quarterly ↗ | Jun 30, 2026 | 37d |
| May 7, 2026 | Quarterly ↗ | Mar 31, 2026 | 37d |
| Mar 3, 2026 | Annual ↗ | Dec 31, 2025 | 62d |
| Nov 7, 2025 | Quarterly ↗ | Sep 30, 2025 | 38d |
| Aug 7, 2025 | Quarterly ↗ | Jun 30, 2025 | 38d |
| May 8, 2025 | Quarterly ↗ | Mar 31, 2025 | 38d |
| Feb 28, 2025 | Annual ↗ | Dec 31, 2024 | 59d |
| Nov 12, 2024 | Quarterly ↗ | Sep 30, 2024 | 43d |
| Aug 8, 2024 | Quarterly ↗ | Jun 30, 2024 | 39d |
| May 10, 2024 | Quarterly ↗ | Mar 31, 2024 | 40d |
| Mar 1, 2024 | Annual ↗ | Dec 31, 2023 | 61d |
| Nov 3, 2023 | Quarterly ↗ | Sep 30, 2023 | 34d |
Current reports
| Filed | Disclosed |
|---|---|
| Aug 6, 2026 | Results ↗ |
| Jul 8, 2026 | Other events ↗ |
| Jun 8, 2026 | Shareholder vote ↗ |
| May 7, 2026 | Results ↗ |
| Apr 16, 2026 | Director or officer change ↗ |
| Mar 3, 2026 | Results · Regulation FD ↗ |
| Jan 12, 2026 | Regulation FD ↗ |
| Nov 7, 2025 | Results ↗ |
| Sep 8, 2025 | Regulation FD ↗ |
| Aug 7, 2025 | Results ↗ |
| Aug 5, 2025 | Director or officer change · Shareholder vote ↗ |
| Jul 31, 2025 | Material agreement ↗ |